The WACC of DOD Biotech PCL (DOD.BK) is 8.9%.
| Range | Selected | |
| Cost of equity | 8.60% - 11.10% | 9.85% |
| Tax rate | 16.00% - 23.40% | 19.70% |
| Cost of debt | 4.00% - 11.00% | 7.50% |
| WACC | 7.4% - 10.5% | 8.9% |
| Category | Low | High |
| Long-term bond rate | 2.6% | 3.1% |
| Equity market risk premium | 7.4% | 8.4% |
| Adjusted beta | 0.81 | 0.89 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.60% | 11.10% |
| Tax rate | 16.00% | 23.40% |
| Debt/Equity ratio | 0.3 | 0.3 |
| Cost of debt | 4.00% | 11.00% |
| After-tax WACC | 7.4% | 10.5% |
| Selected WACC | 8.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for DOD.BK:
cost_of_equity (9.85%) = risk_free_rate (2.85%) + equity_risk_premium (7.90%) * adjusted_beta (0.81) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.